Precision Neuroscience Leader joins WoHX
Boston, MA -- October 8: Women's HealthX is pleased to welcome Beacon Biosignals as a Silver Sponsor for this year's event in Boston.
As the life sciences sector faces increasing pressure to meet stringent trial diversity mandates and secure commercial reimbursement, the need for objective, highly validated clinical endpoints has never been more urgent.
Beacon Biosignals is tackling this challenge through its AI-powered precision neuroscience platform, collecting, integrating, and analyzing EEG and sleep data across the full drug development lifecycle.
By building the world's largest clinically validated neurophysiology dataset, Beacon provides biopharma sponsors with the robust quantitative evidence required to accelerate clinical trials and bring targeted, personalized therapies to market faster.
"The company's mission perfectly complements the research and clinical data tracks at Women's HealthX. Throughout the event, life sciences leaders will discuss how capturing representative, real-world biological data is the key to overcoming commercial bottlenecks and ensuring new therapeutics actually reach the women who need them."
To move beyond the limitations of subjective endpoints, biopharma needs scalable, at-home diagnostic capabilities that capture the true physiological impact of new treatments.
Beacon Biosignals is providing the infrastructure to make that a reality. We are delighted to welcome Beacon Biosignals to the Women's HealthX community and look forward to showcasing their work this December.
Women’s HealthX 2026 | From Rhetoric to Results
Encore Boston Harbor | December 3-4 2026
Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems. Join the region's foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.
